Neuren Pharmaceuticals is developing new drug therapies to treat multiple serious neurological conditions, caused by genetic abnormalities or brain injury, that have no or limited approved treatment options. Incorporated in New Zealand and based in Melbourne, Australia, Neuren is listed on the ASX under the code NEU. 2 Chair and CEO message 4 Operating Review 21 Board 22 Executive Team 24 Environmental, Social and Governance (ESG) 31 Directors’ Responsibilities Statement CONTENTS 32 C onsolidated Statement of Profit or Loss and Other Comprehensive Income 33 Consolidated Statement of Financial Position 34 Consolidated Statement of Changes in Equity 35 Consolidated Statement of Cash Flows 36 Notes to the Consolidated Financial Statements 56 Independent Auditor’s Report 59 Additional Information
RkJQdWJsaXNoZXIy MjE2NDg3